Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALL-104 and Imatinib Mesylate in Chronic Myelogenous Leukemia
NCT00415909Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2006
- Primary completion
- May 2013
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TALL-104 in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2006; status: terminated.
02
Drugs
TALL-104
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00415909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415909.